Kyle Fletcher - 13 Jul 2022 Form 4 Insider Report for Celularity Inc (CELU)

Role
General Counsel
Signature
/s/ Keary Dunn, Attorney-in-Fact
Issuer symbol
CELU
Transactions as of
13 Jul 2022
Net transactions value
$0
Form type
4
Filing time
15 Jul 2022, 20:30:03 UTC
Next filing
18 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CELU Class A Common Stock Award $0 +2,297 +6.9% $0.000000 35,432 13 Jul 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CELU Stock Option (Right to Buy) Award $0 +6,735 $0.000000 6,735 13 Jul 2022 Class A Common Stock 6,735 $10.16 Direct F2
transaction CELU Stock Option (Right to Buy) Award $0 +125,000 $0.000000 125,000 13 Jul 2022 Class A Common Stock 125,000 $4.15 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs is subject to time-based vesting over a four-year period, with 25% vesting on the one-year anniversary of the grant date, and the remainder vesting in equal annual installments thereafter so that vested in full on the four-year anniversary of the grant date, and subject to the Reporting Person's continuous service on each vesting date.
F2 This option was granted under the 2021 Plan and shall vest and become exercisable over a four-year period, with 25% of the option vesting on April 13, 2023, and the remainder vesting in equal monthly installments thereafter so that vested in full on April 13, 2026, and subject to the Reporting Person's continuous service on each vesting date.
F3 This option was granted under the 2021 Plan and shall vest and become exercisable over a four-year period, with 25% of the option vesting on the one-year anniversary of the grant date, and the remainder vesting in equal monthly installments thereafter so that vested in full on the four-year anniversary of the grant date, and subject to the Reporting Person's continuous service on each vesting date.